X4 Pharmaceuticals (XFOR) Cost of Revenue (2024 - 2025)
X4 Pharmaceuticals (XFOR) posted Cost of Revenue of $364000.0 for Q4 2025, up 3.7% on a QoQ basis from $351000.0 in Q3 2025, and up 20.53% year-over-year from $302000.0 in Q4 2024.
X4 Pharmaceuticals (XFOR) Cost of Revenue (2024 - 2025) Analysis & Trends
X4 Pharmaceuticals' Cost of Revenue history runs 2 years deep, the most recent figure standing at $364000.0 for Q4 2025.
- Quarterly Cost of Revenue rose 20.53% year-over-year to $364000.0 in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $5.8 million (up 622.33% YoY) and the FY2025 annual result came in at $5.8 million, up 622.33% from the prior year.
- Cost of Revenue was $364000.0 for Q4 2025 at X4 Pharmaceuticals, up from $351000.0 in the prior quarter.
- Across five years, Cost of Revenue topped out at $4.7 million in Q1 2025 and bottomed at $227000.0 in Q3 2024.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cost of Rev (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 66,621.14 Bn | 66,620.85 Bn | - | - |
| 2 | Nanobiotix | 1,915.18 Bn | 1,915.11 Bn | - | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - | - |
| 4 | BeOne Medicines | 471.27 Bn | 466.48 Bn | 1.35 Bn | 167.22 Mn |
| 5 | Vertex Pharmaceuticals | 121.81 Bn | 114.57 Bn | 2.59 Bn | 392.80 Mn |
| 6 | Regeneron Pharmaceuticals | 69.58 Bn | 60.82 Bn | 3.31 Bn | 296.00 Mn |
| 7 | Belite Bio | 62.72 Bn | 62.72 Bn | - | - |
| 8 | Argenx Se | 55.51 Bn | 50.33 Bn | 1.41 Bn | 145.00 Mn |
| 9 | Revolution Medicines | 37.35 Bn | 37.35 Bn | - | - |
| 10 | X4 Pharmaceuticals | 167.90 Mn | -49.15 Mn | 2.20 Mn | 364,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 364,000.00 |
| Dec 31, 2025 | 364,000.00 |
| Sep 30, 2025 | 351,000.00 |
| Sep 30, 2025 | 351,000.00 |
| Jun 30, 2025 | 326,000.00 |
| Jun 30, 2025 | 326,000.00 |
| Mar 31, 2025 | 4.72 Mn |
| Mar 31, 2025 | 4.72 Mn |
| Dec 31, 2024 | 302,000.00 |
| Dec 31, 2024 | 302,000.00 |
| Sep 30, 2024 | 227,000.00 |
| Sep 30, 2024 | 227,000.00 |
| Jun 30, 2024 | 268,000.00 |
| Jun 30, 2024 | 268,000.00 |